Skip to main content
Access Resources

MJFF Publications

181 - 190 of 7370 Results
Title
Year
  • Year
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • OPEN
    Title: No laughing white matter: Reduced integrity of the cortical cholinergic pathways in Parkinson's disease-related cognitive impairment
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.nbd.2023.106243
    Citation Count: 1
  • OPEN
    Title: Novel human pluripotent stem cell-derived hypothalamus organoids demonstrate cellular diversity
    Journal Name: iScience
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.isci.2023.107525
    Citation Count: 0
  • OPEN
    Title: Patients’ Preferences for Adjunctive Parkinson’s Disease Treatments: A Discrete-Choice Experiment
    Journal Name: Patient Preference and Adherence
    Publisher: Informa UK Limited
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.2147/ppa.s420051
    Citation Count: 0
  • RESTRICTED
    Title: Prediction of Parkinson’s disease pathogenic variants using hybrid Machine learning systems and radiomic features
    Journal Name: Physica Medica
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.ejmp.2023.102647
    Best OA location URL:
    Citation Count: 0
  • OPEN
    Title: Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease
    Journal Name: JAMA Neurology
    Publisher: American Medical Association (AMA)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1001/jamaneurol.2023.2338
    Citation Count: 1
  • RESTRICTED
    Title: Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trial
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2023.105511
    Best OA location URL:
    Citation Count: 1
  • OPEN
    Title: Spatially heterogeneous structure-function coupling in haemodynamic and electromagnetic brain networks
    Journal Name: NeuroImage
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.neuroimage.2023.120276
    Citation Count: 1
  • OPEN
    Title: Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
    Journal Name: npj Parkinson's Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1038/s41531-023-00573-2
    Citation Count: 0
  • OPEN
    Title: NeuroBridge: a prototype platform for discovery of the long-tail neuroimaging data
    Journal Name: Frontiers in Neuroinformatics
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fninf.2023.1215261
    Citation Count: 0
  • RESTRICTED
    Title: A blood-based marker of mitochondrial DNA damage in Parkinson’s disease
    Journal Name: Science Translational Medicine
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1126/scitranslmed.abo1557
    Best OA location URL:
    Citation Count: 5
Filters
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.